(Total Views: 422)
Posted On: 09/24/2024 8:10:07 PM
Post# of 148863
Cool that 25% of the 90% of white dudes and dudettes gained 1 stage on REM.
Fast forward to Delta 32 single or double allele deletion due to bubonic plague in Northern Europe. Screech….
“RESULTS Efficacy: Among evaluable patients, both doses of resmetirom were superior to placebo with respect to
the two primary end points. Safety: More than 90% of the patients in each group had adverse events, most of which were mild or moderate in severity. Diarrhea and nausea occurred more often with resmetirom than with placebo. The incidence of serious
adverse events was similar among the groups.
LIMITATIONS AND REMAINING QUESTIONS • The trial lacked clinical-outcomes data to correlate with the histologic data. The trial is planned to con- tinue to 54 months to evaluate liver-related outcomes,
including progression to cirrhosis. • Almost 90% of the participants were White, which limits the generalizability of the findings to other racial
or ethnic groups.”
My take away with few AEs? Hold our beers, we got this!
Fast forward to Delta 32 single or double allele deletion due to bubonic plague in Northern Europe. Screech….
“RESULTS Efficacy: Among evaluable patients, both doses of resmetirom were superior to placebo with respect to
the two primary end points. Safety: More than 90% of the patients in each group had adverse events, most of which were mild or moderate in severity. Diarrhea and nausea occurred more often with resmetirom than with placebo. The incidence of serious
adverse events was similar among the groups.
LIMITATIONS AND REMAINING QUESTIONS • The trial lacked clinical-outcomes data to correlate with the histologic data. The trial is planned to con- tinue to 54 months to evaluate liver-related outcomes,
including progression to cirrhosis. • Almost 90% of the participants were White, which limits the generalizability of the findings to other racial
or ethnic groups.”
My take away with few AEs? Hold our beers, we got this!
(2)
(0)Scroll down for more posts ▼
